Evidence map›Paper›PMID 24441388›Full record

ArticleScientific reports2014

ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload.

Hirotaka Matsuo, Akiyoshi Nakayama, Masayuki Sakiyama, Toshinori Chiba, Seiko Shimizu, Yusuke Kawamura, Hiroshi Nakashima, Takahiro Nakamura, Yuzo Takada, Yuji Oikawa and 17 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 7 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 7 syntheses or guidelines pooled it, 159 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. A meta-analysis of the associations between the Q141K and Q126X ABCG2 gene variants and gout risk.International journal of clinical and experimental pathology · 2015
    Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 9 institutions in 1 country.

Hirotaka Matsuo1] Department of Integrative Physiology and Bio-Nano Medicine National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan [2].
Akiyoshi Nakayama1] Department of Integrative Physiology and Bio-Nano Medicine National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan [2] Medical Group, Headquarters, Iwo-to Air Base Group, Japan Air Self-Defense Force, Iwo-to, Ogasawara, Tokyo 100-2100, Japan [3].
Masayuki SakiyamaDepartment of Integrative Physiology and Bio-Nano Medicine National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
Toshinori ChibaDepartment of Integrative Physiology and Bio-Nano Medicine National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
Seiko ShimizuDepartment of Integrative Physiology and Bio-Nano Medicine National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
Yusuke KawamuraDepartment of Integrative Physiology and Bio-Nano Medicine National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
Hiroshi NakashimaDepartment of Preventive Medicine and Public Health, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
Takahiro Nakamura1] Laboratory for Mathematics, Premedical Course, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan [2] Laboratory for Statistical Analysis, Center for Integrative Medical Sciences, RIKEN, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan.
Yuzo TakadaLaboratory for Biofunctions, The Central Research Institute, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
Yuji OikawaDepartment of Biology, Faculty of Science, Toho University, 2-2-1 Miyama, Funabashi, Chiba 274-8510, Japan.
Tappei TakadaDepartment of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Hirofumi NakaokaDepartment of Integrated Genetics, National Institute of Genetics, 1111 Yata, Mishima, Shizuoka 411-8540, Japan.
Junko AbeDepartment of Integrative Physiology and Bio-Nano Medicine National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
Hiroki InoueDepartment of Integrative Physiology and Bio-Nano Medicine National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
Kenji WakaiDepartment of Preventive Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan.
Sayo KawaiDepartment of Preventive Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan.
Yin Guang1] Department of Preventive Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan [2] Department of Nutritional Sciences, Faculty of Health and Welfare, Seinan Jo Gakuin University, 1-3-5 Ibori, Kokura Kita-ku, Kitakyushu, Fukuoka 803-0835, Japan.
Hiroko NakagawaDepartment of Preventive Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan.
Toshimitsu ItoDepartment of Internal Medicine, Self-Defense Forces Central Hospital, 1-2-24 Ikejiri, Setagaya-ku, Tokyo 154-8532, Japan.
Kazuki NiwaDepartment of Biology, Faculty of Science, Toho University, 2-2-1 Miyama, Funabashi, Chiba 274-8510, Japan.
Ken YamamotoDivision of Genome Analysis, Research Center for Genetic Information, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Yutaka SakuraiDepartment of Preventive Medicine and Public Health, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
Hiroshi SuzukiDepartment of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Tatsuo HosoyaDivision of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, 3-19-18 Shinbashi, Minato-ku, Tokyo 105-8471, Japan.
Kimiyoshi Ichida1] Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, 3-19-18 Shinbashi, Minato-ku, Tokyo 105-8471, Japan [2] Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachiouji, Tokyo 192-0392, Japan.
Toru ShimizuMidorigaoka Hospital, 3-13-1 Makami-cho, Takatsuki, Osaka 569-1121, Japan.
Nariyoshi ShinomiyaDepartment of Integrative Physiology and Bio-Nano Medicine National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
National Defense Medical College · JPNagoya University · JPJikei University School of Medicine · JPToho University · JPUniversity of Tokyo Hospital · JPKyushu University · JPMidorigaoka Hospital · JPNational Institute of Genetics · JPSelf-Defense Forces Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gout is a common disease which results from hyperuricemia. We have reported that the dysfunction of urate exporter ABCG2 is the major cause of renal overload (ROL) hyperuricemia, but its involvement in renal underexcretion (RUE) hyperuricemia, the most prevalent subtype, is not clearly explained so far. In this study, the association analysis with 644 hyperuricemia patients and 1,623 controls in male Japanese revealed that ABCG2 dysfunction significantly increased the risk of RUE hyperuricemia as well as overall and ROL hyperuricemia, according to the severity of impairment. ABCG2 dysfunction caused renal urate underexcretion and induced hyperuricemia even if the renal urate overload was not remarkable. These results show that ABCG2 plays physiologically important roles in both renal and extra-renal urate excretion mechanisms. Our findings indicate the importance of ABCG2 as a promising therapeutic and screening target of hyperuricemia and gout.

Indexed as

AllelesATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily G, Member 2GenotypeHumansHyperuricemiaKidney DiseasesMaleModels, BiologicalNeoplasm ProteinsUric AcidABCG2 protein, humanATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsUric Acid

Identifiers

PMID24441388
PMCPMC3895923
OpenAlexW2004061676

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.